Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin

Auernhammer, Christoph J.; Göke, Burkhard

doi:10.1136/gut.2009.204453

Cited by 76 publications

(62 citation statements)

References 243 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Kweekeboom reported the occurrence of carcinoid crisis was about 1% after peptide receptor radionuclide therapy in 510 patients. (Auernhammer and Goke, 2011) Carcinoid crisis can be engendered by anesthesia, medication (chemotherapy, or radiopharmaceuticals) and various invasive procedures. (Tomassetti et al, 2001) It is worth noting that the event can even occur in apparently symptomatic-stable patients and be provocated by a simple biopsy from the tumor body.…”

Section: Introductionmentioning

confidence: 99%

Somatostatin Analogues Do Not Prevent Carcinoid Crisis

Guo

Tang²

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Carcinoid crisis is a life-threating syndrome of neuroendocrine tumors (NETs) characterized by dramatic blood pressure fluctuation, arrhythmias, and bronchospasm. In the era of booming anti-tumor therapeutics, this has become more important since associated stresses can trigger carcinoid crisis. Somatostatin analogues (SSTA) have been recommended for prophylactic administration before intervention procedures for functioning NETs. However, the efficacy is still controversial. The aim of this article is to review efficacy of SSTA for preventing carcinoid crisis. Materials and Methods: PubMed, Cochrane Controlled trials Register, and EMBASE were searched using 'carcinoid crisis' as a search term combining terms with 'somatostatin'; 'octreotide'; 'lanreotide' and 'pasireotide' until December 2013. Results: Twenty-eight articles were retrieved with a total of fifty-three unique patients identified for carcinoid crisis. The most common primary sites of NETs were the small intestine and respiratory tract. The triggering factors for carcinoid crisis included anesthesia/ surgery (63.5%), interventional therapy (11.5%), radionuclide therapy (9.6%), examination (7.7%), medication (3.8%), biopsy (2%) and spontaneous (2%). No randomized controlled trials (RCTs) were identified and two case-control studies were included to assess the efficacy of SSTA for preventing carcinoid crisis by meta-analysis. The overall pooled risk of perioperative carcinoid crisis was similar despite the prophylactic administration of SSTA (OR 0.44, 95% CI: 0.14 to 1.35, p=0.15). Conclusions: SSTA wasnot helpful for preventing carcinoid crisis based on a meta-analysis of retrospective studies. Attentive monitoring and careful intervention are essential. Future studies with better quality are needed to clarify any effect of SSTA for preventing carcinoid crisis.

show abstract

Section: Introductionmentioning

confidence: 99%

Somatostatin Analogues Do Not Prevent Carcinoid Crisis

Guo

Tang²

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…A large multicentre case series has reported a 5 and 10 year survival rate of 74% and 51% respectively following surgery for LM, however this does not correlate with disease free survival, as 5 year tumour recurrence has been quoted to be as high as 94-97% of patients [15]. Sarmiento et al [19] reported a case series of 170 patients of which 44% had a curative resection and 56% had a debulking of >90% of tumour load whose average 5 year survival rate was 61%, yet with a tumour recurrence rate of 84%.…”

Section: Surgical Management Of Hepatic Metastases In Neuro-endocrinementioning

confidence: 99%

“…An alternative strategy to ensure the future liver remnant is (FLR) >30% is to perform a 2 staged resection [15].…”

Section: Surgical Management Of Hepatic Metastases In Neuro-endocrinementioning

confidence: 99%

An Overview of the Surgical Management of Hepatic Neuroendocrine Metastases

Pathak

Dash

Taylor

et al. 2012

Indian J Surg Oncol

View full text Add to dashboard Cite

Neuroendocrine tumours (NET) frequently metastasise to the liver (NLM) and are associated with significant morbidity and mortality. Numerous treatment options have been implemented both for cure, and to implement disease control. Surgical treatment includes curative resection, palliative cytoreductive resection and transplantation. Complete surgical resection is only possible in a subset of people with NLMs due to excessive metastatic burden and anatomical location. Ablative therapies may be used either as an adjunct to surgery or as a primary treatment. The purpose of the following article is to summarise surgical treatment strategies in the management of patients with hepatic neuroendocrine metastases, based on the available literature.

show abstract

“…However, a large number of patients suffer unresectable tumor. In these cases the main objective of therapy is to control the progression [11].…”

Section: Analysis Of Costs Of Medicinal Product Lanreotide (Somatulinmentioning

confidence: 99%

Analysis of costs of medicinal product lanreotide (somatuline® autogel®) in the treatment of pnet degree grade 1 or 2 (with tumor proliferation index [KI-67]<10%), in adult patients with non-functioning non-metastatic or metastatic tumors

Kulikov¹,

Tischenko²

2016

Pharmacoeconom T&P

View full text Add to dashboard Cite

show abstract

Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin

Abstract: Multimodal treatment options for advanced gastroenteropancreatic neuroendocrine tumours (NET) of jejunum/ileum and of pancreatic origin are reviewed.

Cited by 76 publications

References 243 publications

Somatostatin Analogues Do Not Prevent Carcinoid Crisis

Somatostatin Analogues Do Not Prevent Carcinoid Crisis

An Overview of the Surgical Management of Hepatic Neuroendocrine Metastases

Analysis of costs of medicinal product lanreotide (somatuline® autogel®) in the treatment of pnet degree grade 1 or 2 (with tumor proliferation index [KI-67]<10%), in adult patients with non-functioning non-metastatic or metastatic tumors

Contact Info

Product

Resources

About